Core Viewpoint - The company is accelerating its investment in innovative drugs to achieve its third industrial transformation and upgrade strategy, emphasizing cash flow management and resource optimization [1] Group 1: Innovation and Development - The company has increased its investment in innovative drugs through multiple channels and resources to expedite development [1] - HB0025, a dual antibody developed by the company's subsidiary, has submitted an application for a confirmatory phase III clinical trial for advanced or recurrent endometrial cancer, marking a critical step towards domestic phase III clinical development [1] - The phase II clinical data for non-small cell lung cancer shows significant efficacy, with expectations to initiate phase III clinical trials domestically within the year [1] Group 2: Financial Management - The company maintains a stable cash flow from its core business, providing continuous support for research and development [1] - The financial structure is robust, with smooth financing channels that ensure strong backing for R&D investments [1] - Continuous optimization of resource allocation is aimed at maximizing the value of potential research pipelines [1] Group 3: Market Strategy - The overseas rights transfer of innovative drug products is part of the company's long-term strategy to expand into international markets and realize the value of R&D achievements [1]

| 股票简称：华海药业 | 股票代码：600521 | 公告编号：临 | 号 2025-103 | | --- | --- | --- | --- | | 债券简称：华海转债 | 债券代码：110076 | | | 浙江华海药业股份有限公司 关于获得药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 浙江华海药业股份有限公司（以下简称"公司"）于近日收到国家药品监督管 理局（以下简称"国家药监局"）核准签发的卡络磺钠注射液的《药品注册证书》， 现将相关情况公告如下： 一、药品的基本情况 药品名称：卡络磺钠注射液 剂型：注射剂 规格：5ml：25mg（按 C₁₀H₁₁N₄NaO₅S·3H₂O 计） 申请事项：药品注册（境内生产） 注册分类：化学药品 3 类 申请人：浙江华海药业股份有限公司 药品批准文号：国药准字 H20255532 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品符 合药品注册的有关要求，批准注册，发给药品注册证书。 二、药品其他相关情况 截至目前，公司在卡络磺钠注射液研 ...

每经头条（nbdtoutiao）——始祖鸟深陷"炸山"风波，母公司大中华区新总裁上任才两个多月，被赞"专 业能力深厚"！安踏体育最新回应→ 每经AI快讯，华海药业（SH 600521，收盘价：22.42元）9月22日晚间发布公告称，浙江华海药业股份 有限公司于近日收到国家药品监督管理局核准签发的卡络磺钠注射液的《药品注册证书》。 2024年1至12月份，华海药业的营业收入构成为：成品药销售占比60.32%，原材料及中间体销售占比 38.19%，技术服务占比0.66%，其他业务占比0.55%，其他行业占比0.28%。 截至发稿，华海药业市值为336亿元。 （记者 王晓波） ...

华海药业9月22日公告，公司近日收到国家药品监督管理局核准签发的卡络磺钠注射液《药品注册证 书》。卡络磺钠注射液用于泌尿系统、上消化道、呼吸道和妇产科出血疾病，对泌尿系统疗效较显著， 亦可用于手术出血的预防及治疗等。 ...

Core Viewpoint - Huahai Pharmaceutical (600521.SH) has received the drug registration certificate for Carbetocin Injection from the National Medical Products Administration, indicating a significant regulatory approval for the company’s product in the market [1] Group 1: Product Information - Carbetocin Injection is indicated for bleeding diseases in the urinary system, upper digestive tract, respiratory tract, and gynecology [1] - The product shows notable efficacy in treating urinary system conditions and can also be used for the prevention and treatment of surgical bleeding [1]

华海药业（600521）(600521.SH)公告，公司近日收到国家药品监督管理局核准签发的卡络磺钠注射液 的《药品注册证书》。卡络磺钠注射液用于泌尿系统、上消化道、呼吸道和妇产科出血疾病，对泌尿系 统疗效较显著，亦可用于手术出血的预防及治疗等。 ...

华海药业公告，公司于近日收到国家药监局核准签发的卡络磺钠注射液的《药品注册证书》。卡络磺钠 注射液主要用于泌尿系统、上消化道、呼吸道和妇产科出血疾病，2024年国内市场销售金额预计约2.5 亿元。公司已在该项目上投入研发费用约712万元。此次获批将丰富公司产品线，提升市场竞争力。 ...

Core Viewpoint - Huahai Pharmaceutical's stock has experienced a decline of 5.04% over the past three days, closing at 22.43 CNY per share with a market capitalization of 33.583 billion CNY [1] Company Overview - Zhejiang Huahai Pharmaceutical Co., Ltd. was established on February 28, 2001, and listed on March 4, 2003. The company specializes in the research, production, and sales of various dosage forms of generic drugs, biological drugs, innovative drugs, and specialty raw materials [1] - The revenue composition of the company is as follows: finished drug sales account for 61.86%, raw materials and intermediates sales for 36.75%, other sales for 0.78%, and technical services for 0.62% [1] Fund Holdings - According to data, one fund under Jiashi Fund holds a significant position in Huahai Pharmaceutical. Jiashi Xinhe One-Year Holding Period Mixed A (008664) held 50,300 shares in the second quarter, representing 0.39% of the fund's net value, making it the sixth-largest holding [2] - The fund has incurred a floating loss of approximately 26,700 CNY today, with a total floating loss of 59,900 CNY during the three-day decline [2] Fund Manager Information - The fund manager of Jiashi Xinhe One-Year Holding Period Mixed A (008664) is Yang Yechao, who has been in the position for 9 years and 303 days. The total asset size of the fund is 1.878 billion CNY [3] - During Yang Yechao's tenure, the best fund return was 40.38%, while the worst return was -4.07% [3]

Group 1 - The core point of the article is that Huahai Pharmaceutical (600521) announced a non-public offering of shares, with a total of 41,152,263 shares to be listed [1] - The subscription method for the shares is offline, indicating a targeted approach to raising capital [1] - The listing date for the shares is set for September 25, 2025, marking a future event for investors to consider [1]

Group 1 - Company Huahai Pharmaceutical announced that approximately 41.15 million restricted shares will be unlocked and listed for trading on September 25, 2025, accounting for about 2.75% of the company's total share capital [1] - For the year 2024, the revenue composition of Huahai Pharmaceutical is as follows: finished drug sales account for 60.32%, raw materials and intermediates sales account for 38.19%, technical services account for 0.66%, other businesses account for 0.55%, and other industries account for 0.28% [1] - The current market capitalization of Huahai Pharmaceutical is 34.4 billion yuan [2]